Find Clinical Trial

Home » Find Clinical Trials » Safety and efficacy of S 33138 versus risperidone in schizophrenic patients with predominant positive symptoms: A pilot phase IIa, international, multicentre, randomised, double-blind, parallel-group, controlled study. – CL2-33138-PO-C-RISP-160P-SCHIZOPHRENIA

Safety and efficacy of S 33138 versus risperidone in schizophrenic patients with predominant positive symptoms: A pilot phase IIa, international, multicentre, randomised, double-blind, parallel-group, controlled study. – CL2-33138-PO-C-RISP-160P-SCHIZOPHRENIA

← Back

Study Phase	Phase 2

Therapeutic Area	Neuropsychiatric Diseases

Indication	Schizophrenia

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	S033138

Active Substance Code	S033138

Protocol Code	CL2-33138-007

EudraCT Code	2005-000016-27

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.